Published Articles & Presentations

The information in our publications and presentations should be considered accurate only as of the date of the publications or presentations. We disclaim any obligation to supplement or update the information in these publications and presentations.

To learn more about our innovative technology:

Publications Presentations

Safety of Concomitant Triptan and INP104 Use From the Phase 3 STOP 301 Study in Migraine Patients

Presented at the AAN Annual Meeting, April 22-27, 2023 Authors: Alexander Feoktistov, Robert Vann, Judie Gutierrez, Sutapa Ray, Stephen Shrewsbury, Sheena Aurora Objective: To report safety in migraine patients who used a triptan within 24 hours of INP104 administration. Background: INP104 is a combination of dihydroergotamine mesylate…

Assessment of the Potential for Drug-Drug Interactions Between INP104 and Gepants for Migraine Management Using a Model-based Approach

Presented at the AAN Annual Meeting, April 22-27, 2023 Authors: Sutapa Ray, Bradley Torphy, Shivang Joshi, Robert Vann, Brett Downing, Daniella Fonseca, Stephen Shrewsbury, Sheena Aurora Objective: To predict whether coadministration of INP104 and gepants for migraine management results in potential drug–drug interactions (DDIs). Background: Nasally administered dihydroergotamine mesylate…

Safety and Efficacy of Concomitant Erenumab and INP104 Use From the Phase 3 STOP 301 Study in Migraine Patients

Presented at the AAN Annual Meeting, April 22-27, 2023 Authors: Zubair Ahmed, Robert Vann, Christopher Fitzpatrick, Sutapa Ray, Stephen Shrewsbury, Sheena Aurora Objective: To report safety and efficacy in migraine patients who concomitantly used erenumab and INP104 over 24 weeks. Background: Breakthrough migraine attacks can occur while…

2 3 4